Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2016 / Cilt: 50 - Sayı: 1

Kolorektal dışı kanserlerin karaciğer metastazlarında radyofrekans ablasyon yöntemininin etkinliğinin değerlendirilmesi

Efficacy of Radiofrequency Ablation in the Treatment of Hepatic Metastases of Non-Colorectal Cancers

Pages
60–69
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mortality occurred in 9 (32%) patients due to disseminated disease.Conclusion: Our results indicate that RFA can be a promising therapeutic alternative in patients with hepatic metastasis of non-colorectal cancers, particularly breast cancer and neuroendocrine tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Efficacy of radiofrequency ablation in the treatment of hepatic metastases of non-colorectal cancersObjective: To determine the efficacy of radiofrequency ablation (RFA) method in treatment of hepatic metastases of non-colorectal cancers.
📊
Key Findings & Data:Material and Method: This retrospective cohort included 28 patients (17 women, 11 men) diagnosed with a total of 101 hepatic metastases of non-colorectal cancers.
💡
Conclusion & Impact:Mortality occurred in 9 (32%) patients due to disseminated disease.Conclusion: Our results indicate that RFA can be a promising therapeutic alternative in patients with hepatic metastasis of non-colorectal cancers, particularly breast cancer and neuroendocrine tumors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Efficacy of radiofrequency ablation in the treatment of hepatic metastases of non-colorectal cancersObjective: To determine the efficacy of radiofrequency ablation (RFA) method in treatment of hepatic metastases of non-colorectal cancers. Material and Method: This retrospective cohort included 28 patients (17 women, 11 men) diagnosed with a total of 101 hepatic metastases of non-colorectal cancers. RFA under sonographic guidance was administered to 95 (94.1%) of lesions, while surgical resection was performed for 6 (5.9%) metastases. At the time of diagnosis, 10 (35.7%) of patients had a single lesion; whereas 18 (64.3%) patients had multiple lesions. Average number of ablated lesions was 2 (range, 1 to 6) and their average diameter was 2.4 cm (range, 0.9-5.2 cm). All patients routinely received chemoradiotherapy.Results: Portal venous thrombosis and liver abscess were detected after RFA in 1 (3.5%) and 2 patients (7%), respectively. Mean duration of follow-up was 17 months (range, 1-51 months) and complete ablation was accomplished in 17 (76%) of our series. Thirteen sessions of repetitive RFA was performed in 7 cases with recurrent disease. During the follow-up period, widespread hepatic metastases and extrahepatic disease were encountered in 6 (21%) and 16 (57%) patients, respectively. Mortality occurred in 9 (32%) patients due to disseminated disease.Conclusion: Our results indicate that RFA can be a promising therapeutic alternative in patients with hepatic metastasis of non-colorectal cancers, particularly breast cancer and neuroendocrine tumors. Number of lesions is the most important parameter likely to affect the overall and disease free rates of survival.

Özet

Amaç: Kolorektal dışı kanserlerin karaciğer metastazlarında radyofrekans ablasyon (RFA) yönteminin tedavideki etkinliğinin değerlendirilmesi. Gereç ve Yöntem: Karaciğere metastatik kolorektal dışı kanser tanısı almış, toplam lezyon sayısı 101 olan 28 hasta (17 kadın, 11 erkek) retrospektif kohort çalışmamıza dahil edildi. Çalışmamızda 95 (%94.1) lezyona ultrasonografi eşliğinde RFA uygulanırken, 6 (%5.9) lezyona cerrahi rezeksiyon yapılmıştı. Tanı anında 10 (%35.7) olguda tek lezyon, 18 (%64.3) olguda multipl lezyon bulunmaktaydı. Ablasyon yapılan ortalama lezyon sayısı 2 ve ortalama boyut 2.4 (0.9-5.2) cm olarak belirlendi. Tüm olgular kemoradyoterapi almıştı.Bulgular: RFA sonrası 1 (%3.5) olguda portal ven trombozu, 2 olguda (%7) karaciğer apsesi gelişti. Ortalama takip süresi 17 aydı. 17 (%76) olguda ilk takipte tam ablasyon sağlandı. Rekürrens saptanan 7 olguda 13 seans reRFA uygulandı. Takipte 6 (%21) olguda yaygın hepatik metastaz, 16 (%57) olguda ekstrahepatik hastalık izlendi. 9 (%32) olgu yaygın hastalık nedeniyle kaybedildi.Sonuç: Sonuçlarımız RFA'nın kolorektal dışı kanserlerin karaciğer metastazlarında, özellikle de meme kanseri ve nöroendokrin tümörlere ait metastazlarda umut verici bir tedavi alternatifi olduğunu göstermektedir. Hastalıksız ve genel sağkalımı etkileyen en önemli parametre ise lezyon sayısı olarak görülmektedir.

🔖

Cite This Article

KALKAN, D. O., YÜCEL, C., OKTAR, S. Ö., ŞARE, M., BENEKLİ, M. (2016). Kolorektal dışı kanserlerin karaciğer metastazlarında radyofrekans ablasyon yöntemininin etkinliğinin değerlendirilmesi. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 50 - Sayı: 1, 60–69. https://ajindex.com/articles/364045

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28: 493- 508. [CrossRef] Zealley IA, Skehan SJ, Rawlinson J, Coates G, Nahmias C, Somers S. Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet. Radiographics 2001; 21: S55-69. [CrossRef] Berber E, Tsinberg M, Tellioglu G, Simpfendorfer CH, Siperstein AE. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 2008; 12: 1967-72. [CrossRef] Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiology 2013; 266: 407-30. [CrossRef] de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000; 175: 1619-25. [CrossRef] Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, et al; Association Française de Chirurgie. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006; 244: 524-35. [CrossRef] Yun BL, Lee JM, Baek JH, Kim SH, Lee JY, Han JK, et al. Radiofrequency ablation for treating liver metastases from a non- colorectal origin. Korean J Radiol 2011; 12: 579-87. [CrossRef] Lindell G, Ohlsson B, Saarela A, Andersson R, Tranberg KG. Liver resection of noncolorectal secondaries. J Surg Oncol 1998; 69: 66-70. [CrossRef] Buell JF, Rosen S, Yoshida A, Labow D, Limsrichamrern S, Cronin DC, et al. Hepatic resection: effective treatment for primary and secondary tumors. Surgery 2000; 128: 686-93. [CrossRef] Treska V, Liska V, Skalicky T, Sutnar A, Treskova I, Narsanska A, et al. Non-colorectal liver metastases: surgical treatment options. Hepatogastroenterology 2012; 59: 245-8.
  2. Elias D, Lasser PH, Montrucolli D, Bonvallot S, Spielmann M. Hepatectomy for liver metastases from breast cancer. Eur J Surg Oncol 1995; 21: 510-3. [CrossRef] Pocard M, Pouillart P, Asselain B, Salmon R. Hepatic resection in metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol 2000; 26: 155-9. [CrossRef] Sofocleous CT, Nascimento RG, Gonen M, Theodoulou M, Covey AM, Brody LA, et al. Radiofrequency ablation in the management of liver metastases from breast canc